Veloxis CEO considers label expansion and acquisitions to increase growth

Danish-American drug group Veloxis Pharmaceuticals has no research and development department, but, according to CEO Craig Collard, the company has several other opportunities to increase sales now that the main asset has started to yield profit.

Photo: Veloxis

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles